Repligen closes acquisition of BioLife Solutions

Repligen Corporation announced on October 6, 2026 that it had completed its previously announced acquisition of BioLife Solutions, Inc., a company that develops and supplies tools and services used in processing cells for therapies in the cell and gene therapy space.¹

Under the terms of the deal, BioLife stockholders received $11.25 in cash per share along with 0.1442 shares of Repligen common stock for each share they held, with any fractional shares paid out in cash.¹ The transaction structure involved a merger agreement dated July 21, 2026, under which a Repligen subsidiary first merged into BioLife, with BioLife then merging into a second Repligen subsidiary, leaving that entity as a wholly owned subsidiary of Repligen.¹

Repligen CEO Olivier Loeillot said BioLife's offerings would expand the company's presence in the growing cell therapy market by adding a consumables business the company described as high-margin with recurring revenue.¹ The release noted that BioLife's biopreservation media line, anchored by its CryoStor product, is used in 18 therapies that have received commercial approval and in most U.S. commercially sponsored clinical trials involving cell-based therapies.¹

As a result of the closing, BioLife ceased to exist as a separate legal entity and no longer meets Nasdaq listing requirements.¹ BioLife notified Nasdaq on October 6, 2026 that the mergers had closed,¹ and the company said it plans to file paperwork with the SEC to deregister its stock and end its public reporting obligations.

Repligen said it would provide more detail on the deal's expected effect on its 2026 financial outlook during its upcoming third quarter earnings call.¹ Perella Weinberg Partners and Goldman Sachs advised Repligen, while Centerview Partners advised BioLife, according to the filing.